Can I read Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification on EtoBox?

Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification by Jeffrey L. Cummings; Amanda M. Leisgang Osse; Jefferson W. Kinney is a Medicine article available to read on EtoBox.

What is Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification about?

Novel agents addressing non-amyloid, non-tau targets in Alzheimer’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified in the Common Alzheimer’s Disease Research Ontology (CADRO) are represented by novel agents in trials. Inflammation and synaptic plasticity/neuroprotection are the CADRO categories with the largest number of novel candidate therapies. Within these categories, there are few overlapping targets among the test agents. Additional categories being evaluated include apolipoprotein E \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\varepsilon$$\end{document}ε 4 (__APOE4__) effects, lipids and lipoprotein receptors, neurogenesis, oxidative stress, bioenergetics and metabolism, vascular factors, cell death, growth factors and hormones, circadian rhythm, and epigenetic regulators. We highlight current drugs being tested within these categories and their mechanisms. Trials will be informative regarding which

Who reads Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification?

Author

Jeffrey L. Cummings; Amanda M. Leisgang Osse; Jefferson W. Kinney

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)